Intensified treatment and control efforts since the early 2000s have dramatically reduced the
burden of Plasmodium falciparum malaria. However, drug resistance threatens to derail this …

Highlights•The antimalarial pipeline has been enriched with new molecules and
targets.•The antimalarial target compound and product profiles have been redefined.•In …

Artemisinin combination therapies (ACTs) are highly effective at treating uncomplicated
Plasmodium falciparum malaria, but the emergence of the new pfkelch13 R561H mutation in …

Management of uncomplicated malaria worldwide is threatened by the emergence in Asia of
Plasmodium falciparum carrying variants of the pfk13 locus and exhibiting reduced …

Artemether–lumefantrine (AL) and artesunate–amodiaquine (AS-AQ) are the most
commonly used artemisinin-based combination therapies (ACT) for treatment of …

Multidrug-resistant Plasmodium falciparum parasites have emerged in Cambodia and
neighboring countries in Southeast Asia, compromising the efficacy of first-line antimalarial …

Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

Background Recent cases of clinical failure in malaria patients in the United Kingdom (UK)
treated with artemether-lumefantrine have implications for malaria chemotherapy worldwide …

Studies of the susceptibility of Plasmodium falciparum to the artemisinin family of
antimalarial drugs provide a complex picture of partial resistance (tolerance) associated with …

Artemisinin and its derivatives (ART) are the cornerstone of malaria treatment as part of
artemisinin combination therapy (ACT). However, reduced susceptibility to artemisinin as …